Theriva Biologics, Inc. (TOVX) Financials

TOVX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 38.2 million 22.8 million
Dec. 31, 2025 38.2 million 22.9 million
Sept. 30, 2025 30.8 million 24.1 million
June 30, 2025 35.8 million 25.2 million

TOVX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -2.5 million 135000
Dec. 31, 2025 -2.9 million 153000
Sept. 30, 2025 -4.3 million 228000
June 30, 2025 -4.7 million 173000

TOVX Net Income

No data available :(

TOVX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 14.4 million 1.5 million 2.0 million
Dec. 31, 2025 13.1 million 1.7 million 352000
Sept. 30, 2025 7.5 million 1.7 million 433000
June 30, 2025 12.1 million 1.6 million 1.2 million

TOVX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 41.1 million
Dec. 31, 2025 12.1 million
Sept. 30, 2025 9.7 million
June 30, 2025 6.8 million

TOVX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 355000 2.1 million -
Dec. 31, 2025 - 1.1 million 931000 -
Sept. 30, 2025 19000 2.6 million 1.9 million -
June 30, 2025 16000 2.0 million 11.2 million -

TOVX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 300000 24000
Dec. 31, 2025 - 27000
Sept. 30, 2025 - -
June 30, 2025 - 27000

TOVX

Price: $0.26

52 week price:
0.16
0.86

Earnings Per Share: -0.58 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 10.1 million

Links: